$108 Million is the total value of CAXTON CORP's 29 reported holdings in Q3 2018. The portfolio turnover from Q2 2018 to Q3 2018 was 32.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SBBP | Buy | STRONGBRIDGE BIOPHARMA PLC | $30,530,000 | -5.7% | 6,294,789 | +16.6% | 28.22% | +146.6% |
| MEIP | Sell | MEI PHARMA INC | $15,855,000 | -8.6% | 3,678,600 | -16.4% | 14.66% | +139.2% |
| SPY | Sell | SPDR S&P 500 ETF TRput | $14,908,000 | -92.3% | 51,279 | -92.8% | 13.78% | -79.8% |
| Sell | GARRISON CAP INC | $9,212,000 | +1.3% | 1,112,517 | -0.5% | 8.52% | +165.0% | |
| MTEM | Buy | MOLECULAR TEMPLATES INC | $8,620,000 | +56.4% | 1,599,241 | +51.8% | 7.97% | +309.2% |
| CMFN | Buy | CM FIN INC | $7,698,000 | -2.6% | 895,173 | +0.8% | 7.12% | +154.8% |
| SCYX | Buy | SCYNEXIS INC | $5,190,000 | +7.1% | 4,325,000 | +46.4% | 4.80% | +180.3% |
| AMLP | Sell | ALPS ETF TRalerian mlp | $4,469,000 | +5.6% | 418,416 | -0.2% | 4.13% | +176.1% |
| BRKB | BERKSHIRE HATHAWAY INC DELcl b new | $1,994,000 | +14.7% | 9,312 | 0.0% | 1.84% | +200.2% | |
| JBGS | JBG SMITH PPTYS | $1,516,000 | +1.0% | 41,170 | 0.0% | 1.40% | +164.3% | |
| PCG | PG&E CORP | $1,035,000 | +8.0% | 22,500 | 0.0% | 0.96% | +182.3% | |
| UHAL | AMERCO | $963,000 | +0.1% | 2,700 | 0.0% | 0.89% | +161.8% | |
| TPIV | Sell | TAPIMMUNE INC | $738,000 | -7.5% | 81,540 | -3.7% | 0.68% | +141.8% |
| KURA | Buy | KURA ONCOLOGY INC | $607,000 | +103.0% | 34,708 | +111.4% | 0.56% | +429.2% |
| ACRS | Buy | ACLARIS THERAPEUTICS INC | $577,000 | +47.9% | 39,755 | +103.7% | 0.53% | +286.2% |
| ARQL | Buy | ARQULE INC | $511,000 | +609.7% | 90,254 | +596.5% | 0.47% | +1788.0% |
| KALA | New | KALA PHARMACEUTICALS INC | $506,000 | – | 51,259 | +100.0% | 0.47% | – |
| CTIC | New | CTI BIOPHARMA CORP | $427,000 | – | 197,459 | +100.0% | 0.40% | – |
| Sell | INTEC PHARMA LTD JERUSALEM | $364,000 | +27.7% | 64,396 | -0.6% | 0.34% | +232.7% | |
| ABDC | Buy | ALCENTRA CAP CORP | $345,000 | -2.5% | 57,677 | +4.2% | 0.32% | +155.2% |
| EIGR | New | EIGER BIOPHARMACEUTICALS INC | $306,000 | – | 25,494 | +100.0% | 0.28% | – |
| CPRX | Buy | CATALYST PHARMACEUTICALS INC | $276,000 | +162.9% | 72,967 | +115.9% | 0.26% | +589.2% |
| SBPH | New | SPRING BK PHARMACEUTICALS IN | $253,000 | – | 20,986 | +100.0% | 0.23% | – |
| FPACU | Buy | FAR PT ACQUISITION CORPunit 06/01/2025 | $237,000 | +5.3% | 23,030 | +4.2% | 0.22% | +173.8% |
| DRNA | New | DICERNA PHARMACEUTICALS INC | $225,000 | – | 14,724 | +100.0% | 0.21% | – |
| SNSS | Buy | SUNESIS PHARMACEUTICALS INC | $222,000 | +115.5% | 111,217 | +128.3% | 0.20% | +469.4% |
| MRNS | Buy | MARINUS PHARMACEUTICALS INC | $202,000 | +117.2% | 20,180 | +54.0% | 0.19% | +466.7% |
| CACC | New | CREDIT ACCEP CORP MICH | $201,000 | – | 459 | +100.0% | 0.19% | – |
| SRRA | Buy | SIERRA ONCOLOGY INC | $190,000 | +90.0% | 111,898 | +231.7% | 0.18% | +402.9% |
| TCAP | Exit | TRIANGLE CAP CORP | $0 | – | -26,286 | -100.0% | -0.11% | – |
| GTXI | Exit | GTX INC DEL | $0 | – | -49,805 | -100.0% | -0.27% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MOLECULAR TEMPLATES INC | 24 | Q2 2023 | 30.7% |
| STRONGBRIDGE BIOPHARMA PLC | 22 | Q3 2021 | 73.1% |
| GARRISON CAP INC | 18 | Q3 2020 | 9.9% |
| BERKSHIRE HATHAWAY INC DEL | 17 | Q3 2019 | 5.8% |
| EIGER BIOPHARMACEUTICALS INC | 17 | Q3 2022 | 1.7% |
| AGILE THERAPEUTICS INC | 16 | Q1 2018 | 55.5% |
| KALA PHARNACEUTICALS INC | 16 | Q4 2021 | 17.6% |
| CM FIN INC | 16 | Q1 2019 | 7.8% |
| SYNTA PHARMACEUTICALS CORP | 15 | Q2 2016 | 99.9% |
| CTI BIOPHARMA CORP | 14 | Q4 2021 | 8.7% |
View CAXTON CORP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Addex Therapeutics Ltd. | February 14, 2023 | 718,849 | 0.9% |
| Cardiff Oncology, Inc. | February 14, 2023 | 983,607 | 2.2% |
| Rezolute, Inc. | February 14, 2023 | 1,860,518 | 5.0% |
| Xeris Biopharma Holdings, Inc. | February 14, 2023 | 5,973,324 | 4.4% |
| CTI BIOPHARMA CORP | February 14, 2022 | 2,239,300 | 2.3% |
| Sierra Oncology, Inc. | February 14, 2022 | 1,119,322 | 7.0% |
| Strongbridge Biopharma plcSold out | January 05, 2022 | 0 | 0.0% |
| SUNESIS PHARMACEUTICALS INCSold out | February 16, 2021 | 0 | 0.0% |
| Alcentra Capital Corp | February 14, 2020 | 1,005,000 | 7.8% |
| Garrison Capital Inc. | February 14, 2020 | 1,223,096 | 7.6% |
View CAXTON CORP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
View CAXTON CORP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.